| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/24/2002 | DE10126344A1 Apoptose-induzierende DNA-Sequenzen Apoptosis-inducing DNA sequences |
| 01/24/2002 | DE10032608A1 Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte For microsatellite instability (MSI +) - related tumors genes and their gene |
| 01/24/2002 | CA2418391A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 01/24/2002 | CA2418146A1 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 01/24/2002 | CA2416986A1 Crf2 ligands in combination therapy |
| 01/24/2002 | CA2416693A1 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | CA2416452A1 Novel proteins and nucleic acids encoding same |
| 01/24/2002 | CA2416445A1 Human rrp sequences and methods of use |
| 01/24/2002 | CA2415938A1 Alpha-msh related compounds and methods of use |
| 01/24/2002 | CA2415751A1 Masp-2, a complement-fixing enzyme, and uses for it |
| 01/24/2002 | CA2415690A1 Tetraspan protein and uses thereof |
| 01/24/2002 | CA2415347A1 Adenovirus vectors comprising introns |
| 01/24/2002 | CA2415128A1 An implantable or insertable therapeutic agent delivery device |
| 01/23/2002 | EP1174514A1 Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement |
| 01/23/2002 | EP1174501A1 Gene expression base sequences for therapeutic use and drugs for gene therapy |
| 01/23/2002 | EP1174129A1 Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173608A1 Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| 01/23/2002 | EP1173600A2 Cationic peg-lipids and methods of use |
| 01/23/2002 | EP1173598A1 A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
| 01/23/2002 | EP1173597A1 Expression of heterologous genes from an ires translational cassette in retroviral vectors |
| 01/23/2002 | EP1173596A2 Methods, compositions, and cells for encapsidating recombinant vectors in aav particles |
| 01/23/2002 | EP1173589A1 Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| 01/23/2002 | EP1173573A1 Method for down-regulating il5 activity |
| 01/23/2002 | EP1173571A2 Human ion channel proteins |
| 01/23/2002 | EP1173569A1 Synthetic signalling molecules |
| 01/23/2002 | EP1173568A2 Laminin 2 and methods for its use |
| 01/23/2002 | EP1173567A2 Tribonectins |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173564A1 Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension |
| 01/23/2002 | EP1173563A1 Compositions and methods for the treatment of tumour |
| 01/23/2002 | EP1173562A2 Inhibition of histone deacetylase |
| 01/23/2002 | EP1173561A2 Non-invasive method for detecting target rna |
| 01/23/2002 | EP1173560A1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof |
| 01/23/2002 | EP1173556A1 Forms of prostate specific antigen (psa) specific for benign prostatic hyperplasia (bph) and methods of using such |
| 01/23/2002 | EP1173551A2 Pseudotyped retroviral vector for gene therapy of cancer |
| 01/23/2002 | EP1173550A1 Method for diminishing specific immune reactions |
| 01/23/2002 | EP1173479A1 49 human secreted proteins |
| 01/23/2002 | EP1173478A1 49 human secreted proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173475A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients |
| 01/23/2002 | EP1173474A1 Membrane disruptive peptides covalently oligomerized |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173461A1 50 human secreted proteins |
| 01/23/2002 | EP1173457A1 Polynucleotide and polypeptide sequences encoding human organic anion transporter 6(hoatp6) and screening methods thereof |
| 01/23/2002 | EP1173414A1 N-protected amines and their use as prodrugs |
| 01/23/2002 | EP1173225A2 Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors |
| 01/23/2002 | EP1173224A1 Polyethyleneimine:dna formulations for aerosol delivery |
| 01/23/2002 | EP1173217A2 Enhanced delivery of nucleic acid-based drugs |
| 01/23/2002 | EP1173204A1 Mutant human cd80 and compositions for and methods of making and using the same |
| 01/23/2002 | EP0888545B1 Super-paramagnetic particles with increased r 1 relaxivity, processes for producing said particles and use thereof |
| 01/23/2002 | EP0884947A4 Dna vaccination for induction of suppressive t cell response |
| 01/23/2002 | EP0813539A4 Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| 01/23/2002 | EP0755258B1 Methods of treating disease using sertoli cells and allografts or xenografts |
| 01/23/2002 | EP0696205B1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 01/23/2002 | CN1332801A Connective tissue growth factor (CTGF) and methods of use |
| 01/23/2002 | CN1332799A Cancer cell vaccine |
| 01/23/2002 | CN1332748A Isolated nucleic acid molecules which encodt T cell inducible factors (TIFs), proteins encoded, and uses thereof |
| 01/23/2002 | CN1332240A Superoxide dismutase-4 |
| 01/22/2002 | US6340673 Administering at or near a site of a tumor of tumorigenic disease a herpes simplex virus vector lacking an expressible .gamma..sub.1 34.5 gene, whereby the growth of tumor is suppressed |
| 01/22/2002 | US6340595 A library of unique expressible nucleic acids within a multiplicity of compartments consisting of adenoviral vectors that are introduced into replication defective host cells; for determining functions of nucleic acid sequences |
| 01/22/2002 | US6340591 Integrative protein-DNA cochleate formulations and methods for transforming cells |
| 01/17/2002 | WO2002004953A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 01/17/2002 | WO2002004952A2 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 01/17/2002 | WO2002004684A1 Role of pph1 gene in pulmonary hypertension |
| 01/17/2002 | WO2002004637A1 Myocardium-specific promoter |
| 01/17/2002 | WO2002004636A1 NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS |
| 01/17/2002 | WO2002004623A2 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 01/17/2002 | WO2002004618A1 Methods of producing and using a human microglial cell line |
| 01/17/2002 | WO2002004616A1 RECOMBINANT α-L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF |
| 01/17/2002 | WO2002004608A2 Regulation of human oligopeptidase a-like enzyme |
| 01/17/2002 | WO2002004605A2 Stimulation of cellular regeneration and differentiation in the inner ear |
| 01/17/2002 | WO2002004604A2 Immortalized human microglia cell and continuous cell line |
| 01/17/2002 | WO2002004599A2 Placental protein having multiple egf-like domains |
| 01/17/2002 | WO2002004522A2 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 01/17/2002 | WO2002004514A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/17/2002 | WO2002004513A2 Down syndrome critical region 1-like 1 proteins |
| 01/17/2002 | WO2002004511A2 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS |
| 01/17/2002 | WO2002004509A2 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 01/17/2002 | WO2002004493A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/17/2002 | WO2002004487A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 01/17/2002 | WO2002004028A1 Methods of modulating wound healing and angiogenesis |
| 01/17/2002 | WO2002004027A1 Purification of plasmid dna by hydrophobic interaction chromatography |
| 01/17/2002 | WO2002004026A2 Use of a retrotransposon as promoter in gene therapy |
| 01/17/2002 | WO2002004019A2 Use of strains of the parapox ovis virus against organ fibrosis |
| 01/17/2002 | WO2002004002A2 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals |
| 01/17/2002 | WO2002003961A1 Microspheres and adjuvants for dna vaccine delivery |
| 01/17/2002 | WO2001062786A3 Tlp peptides and dna sequences coding the same |
| 01/17/2002 | WO2001055370A3 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 01/17/2002 | WO2001054672A3 Closure of bacterial ghosts |
| 01/17/2002 | WO2001049722A3 New actinobacillus pleuropneumoniae outer membrane protein and its uses |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001046228A3 Nucleic acid vaccination |
| 01/17/2002 | WO2001040455A3 Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals |
| 01/17/2002 | WO2001040272A3 In situ bioreactors and methods of use thereof |
| 01/17/2002 | WO2001034771A3 METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME 18q RELATED DISORDERS |
| 01/17/2002 | WO2001034769A3 24 human secreted proteins |
| 01/17/2002 | WO2001032706A3 Novel human transporter proteins and polynucleotides encoding the same |
| 01/17/2002 | WO2001031051A3 Antisense modulation of protein kinase c-theta expression |